Prevention of HIV-2 and SIVSM infection in cynomolgus monkeys by active or passive immunization.
We have established experimental infection with HIV-2 and SIVsm in cynomolgus monkeys and successfully used these models for vaccine experiments. Protection against homologous HIV-2 infection was demonstrated in two of two monkeys immunized with a Triton-X100-treated whole HIV-2SBL-6669 vaccine in incomplete Freund's adjuvant and in 2 of 4 monkeys immunized with a formalin-inactivated whole HIV-2 vaccine in RIBI adjuvant. Monkeys preinfected with a live poorly replicating HIV-2 strain were shown to develop cross-protection against SIV-induced disease. We have shown also that HIV-2 and SIVsm infection in cynomolgus monkeys can be prevented by passive immunization. These results raise hope for effective immunization against HIV infections in humans.
Biberfield
G
G
Department of Immunology, National Bacteriological Laboratory, Stockholm, Sweden.
Putkonen
P
P
Thorstensson
R
R
Norrby
E
E
D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000276:immunology; D003429:Cross Reactions; D015483:HIV Antibodies / Q000096:biosynthesis / Q000276:immunology; D015658:HIV Infections / Q000517:prevention & control; D015498:HIV-2 / Q000276:immunology*; D007116:Immunization, Passive; D008252:Macaca fascicularis / Q000276:immunology; D016097:Simian Acquired Immunodeficiency Syndrome / Q000517:prevention & control; D015302:Simian Immunodeficiency Virus / Q000276:immunology*; D014611:Vaccination; D014765:Viral Vaccines / Q000276:immunology*
D016915:AIDS Vaccines; D000914:Antibodies, Viral; D015483:HIV Antibodies; D014765:Viral Vaccines